Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(4.78)
# 120
Out of 5,182 analysts
52
Total ratings
64.58%
Success rate
52.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Buy | $80 → $100 | $69.81 | +43.25% | 6 | Apr 7, 2026 | |
| AURA Aura Biosciences | Reiterates: Buy | $22 | $6.63 | +231.83% | 2 | Mar 30, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Neutral | $60 → $53 | $52.62 | +0.72% | 3 | Mar 25, 2026 | |
| STRO Sutro Biopharma | Upgrades: Buy | $10 → $28 | $25.71 | +8.91% | 2 | Mar 24, 2026 | |
| NBP NovaBridge Biosciences | Reiterates: Buy | $9 | $2.48 | +262.90% | 2 | Mar 16, 2026 | |
| ERAS Erasca | Maintains: Buy | $15 → $20 | $17.06 | +17.23% | 3 | Mar 13, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $4.97 | +161.57% | 1 | Mar 10, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Neutral | $22 → $22 | $21.46 | +0.19% | 3 | Mar 10, 2026 | |
| ENGN enGene Holdings | Reiterates: Buy | $25 | $7.33 | +241.06% | 3 | Mar 9, 2026 | |
| SRRK Scholar Rock Holding | Reiterates: Buy | $58 | $49.90 | +16.23% | 3 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $6.86 | +118.66% | 9 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $21.58 | +85.36% | 1 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $5.14 | +347.47% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $5.45 | +230.28% | 1 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $4 | $1.00 | +300.00% | 1 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $1.07 | +554.21% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $24.64 | +62.34% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $9.71 | +311.95% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $4.95 | +364.65% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $105 | $53.61 | +95.86% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $12.24 | +63.40% | 1 | Aug 8, 2025 |
CG Oncology
Apr 7, 2026
Maintains: Buy
Price Target: $80 → $100
Current: $69.81
Upside: +43.25%
Aura Biosciences
Mar 30, 2026
Reiterates: Buy
Price Target: $22
Current: $6.63
Upside: +231.83%
Terns Pharmaceuticals
Mar 25, 2026
Downgrades: Neutral
Price Target: $60 → $53
Current: $52.62
Upside: +0.72%
Sutro Biopharma
Mar 24, 2026
Upgrades: Buy
Price Target: $10 → $28
Current: $25.71
Upside: +8.91%
NovaBridge Biosciences
Mar 16, 2026
Reiterates: Buy
Price Target: $9
Current: $2.48
Upside: +262.90%
Erasca
Mar 13, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $17.06
Upside: +17.23%
Foghorn Therapeutics
Mar 10, 2026
Reiterates: Buy
Price Target: $13
Current: $4.97
Upside: +161.57%
Day One Biopharmaceuticals
Mar 10, 2026
Downgrades: Neutral
Price Target: $22 → $22
Current: $21.46
Upside: +0.19%
enGene Holdings
Mar 9, 2026
Reiterates: Buy
Price Target: $25
Current: $7.33
Upside: +241.06%
Scholar Rock Holding
Mar 3, 2026
Reiterates: Buy
Price Target: $58
Current: $49.90
Upside: +16.23%
Feb 23, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $6.86
Upside: +118.66%
Feb 12, 2026
Initiates: Buy
Price Target: $40
Current: $21.58
Upside: +85.36%
Feb 10, 2026
Reiterates: Buy
Price Target: $23
Current: $5.14
Upside: +347.47%
Feb 4, 2026
Assumes: Buy
Price Target: $18
Current: $5.45
Upside: +230.28%
Dec 19, 2025
Maintains: Buy
Price Target: $10 → $4
Current: $1.00
Upside: +300.00%
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.07
Upside: +554.21%
Oct 27, 2025
Reiterates: Buy
Price Target: $40
Current: $24.64
Upside: +62.34%
Oct 20, 2025
Reiterates: Buy
Price Target: $40
Current: $9.71
Upside: +311.95%
Sep 29, 2025
Reiterates: Buy
Price Target: $23
Current: $4.95
Upside: +364.65%
Sep 29, 2025
Maintains: Buy
Price Target: $70 → $105
Current: $53.61
Upside: +95.86%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $12.24
Upside: +63.40%